Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
10.1016/j.biochi.2010.06.009 62 KimK.PortisJ
To illustrate the value of a biosimilar in this space, Biogen referenced in its press release a report by the Association for Accessible Medicines which states that spending on therapies for autoimmune diseases has consistently increased by 10% to 25% each year over the past decade
Its not just cosmetic
ClinicalTrials.gov NCT07328100 Efficacy and Safety of Coenzyme I (NAD) for Injection on Vascular Aging
Additionally, for ebselen to become a clinically acceptable radioprotector, there is also a need for establishing its selective radioprotective effects without compromising the tumor radiosensitivity
US$ 25.86
US$ 25.73
US$ 22.63
US$ 24.30
